Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Unhealthy Western diet could accelerate cognitive decline

An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...

Content from other channels on our network

Burnout in health care isn't an 80/20 problem: why a more balanced view is needed and what it means for you and your workplace

A Good Cleaning Schedule: Best Practices for Healthcare Facilities

Conviction and $20K fine follows "serious and prolonged" offending by former podiatrist

Supagas acquires Heeson Medical

Why digital resilience is becoming critical in aged care

The roles of the vendor and EPCs in the project bidding process

ARC awards $82.5m for new research hubs and training centres

Industrial electricity costs could halve by sharing infrastructure

Seeq and Applied Computing partner on industrial AI for energy operations

ARENA opens Round 3 of Solar Sunshot with $250m available

AMCS 2026: APAC Overview and Industry Insights with Michael Bates

Industry transitions from gas to renewable heat: report

Boral launches detailed carbon reporting capability

Study assesses recycled content use in home builds

Smart bin receives 2026 Australian Good Design Award